Novavax, Inc. has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine.   Novavax and Canada expect to finalize an advance purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning as early as 2Q21. This purchase arrangement will be subject to licensure of the Novavax vaccine by Health Canada.   NVX-CoV2373 is currently in Phase II trials to evaluate the safety and immunoge...